Occurrence of internal diseases in the premotor phase of Parkinson’s disease by analyzing a large database covering a whole population

1. Mahlknecht P, Seppi K, Poewe W. The Concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681–97.10.3233/JPD-150685492792426485429Search in Google Scholar

2. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005 Mar;62(3):378–82.10.1001/archneur.62.3.37815767502Search in Google Scholar

3. Csoti I, Jost WH, Reichmann H. Parkinson’s disease between internal medicine and neurology. J Neural Transm. 2016 Jan;123(1):3–17.10.1007/s00702-015-1443-z471346226298728Search in Google Scholar

4. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology. 2018 Jul;91(2):e139–42.10.1212/WNL.000000000000577129898968Search in Google Scholar

5. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology. 2008 May;70(21):1972–9.10.1212/01.wnl.0000312511.62699.a818401018Search in Google Scholar

6. Ajtay A, Oberfrank F, Bereczki D. [Applicability of hospital reports submitted for reimbursement purposes for epidemiological studies based on the example of ischemic cerebrovascular diseases]. Orv Hetil. 2015 Sep;156(38):1540–6.10.1556/650.2015.3025826550700Search in Google Scholar

7. Szatmari S Jr, Ajtay A, Balint M, Takats A, Oberfrank F, Bereczki D. Linking individual patient data to estimate incidence and prevalence of Parkinson’s disease by comparing reports of neurological services and pharmacy prescription refills at a nationwide level. Front Neurol. 2019;10:640.10.3389/fneur.2019.00640659146531275231Search in Google Scholar

8. Szigethy E, Szeles G, Horvath A, Hidvegi T, Jermendy G, Paragh G, et al. Epidemiology of the metabolic syndrome in Hungary. Public Health. 2012 Feb;126(2):143–9.10.1016/j.puhe.2011.11.00322226972Search in Google Scholar

9. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998;17(1):14–20.10.1159/0000261499549720Search in Google Scholar

10. Kivipelto M, Helkala E-L, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002 Aug;137(3):149–55.10.7326/0003-4819-137-3-200208060-0000612160362Search in Google Scholar

11. Paul R, Choudhury A, Kumar S, Giri A, Sandhir R, Borah A. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson’s disease: Involvement of mitochondrial dysfunctions and oxidative stress. PLoS One. 2017;12(2):e0171285.10.1371/journal.pone.0171285Search in Google Scholar

12. Paul R, Choudhury A, Borah A. Cholesterol - A putative endogenous contributor towards Parkinson’s disease. Neurochem Int. 2015 Nov;90:125–33.10.1016/j.neuint.2015.07.025Search in Google Scholar

13. Vikdahl M, Backman L, Johansson I, Forsgren L, Haglin L. Cardiovascular risk factors and the risk of Parkinson’s disease. Eur J Clin Nutr. 2015 Jun;69(6):729–33.10.1038/ejcn.2014.259Search in Google Scholar

14. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May;23(7):1013–8.10.1002/mds.22013Search in Google Scholar

15. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64–74.10.1016/S1474-4422(05)70284-2Search in Google Scholar

16. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec;53(9):1937–42.10.1212/WNL.53.9.1937Search in Google Scholar

17. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009 May;5(2):120–44.10.2174/15733990978816680019442097Search in Google Scholar

18. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008 Nov;4(11):600–9.10.1038/ncpneuro092418978800Search in Google Scholar

19. Biosa A, Outeiro TF, Bubacco L, Bisaglia M. Diabetes mellitus as a risk factor for Parkinson’s disease: a molecular point of view. Mol Neurobiol. 2018 Nov;55(11):8754–63.10.1007/s12035-018-1025-929594935Search in Google Scholar

20. Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, et al. Diabetes mellitus and Parkinson disease. Neurology. 2018 May;90(19):e1654–62.10.1212/WNL.000000000000547529626177Search in Google Scholar

21. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011 May;34(5):1102–8.10.2337/dc10-1333311448221411503Search in Google Scholar

22. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007 Apr;30(4):842–7.10.2337/dc06-201117251276Search in Google Scholar

23. Yang Y-W, Hsieh T-F, Li C-I, Liu C-S, Lin W-Y, Chiang J-H, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore). 2017 Jan;96(3):e5921.10.1097/MD.0000000000005921527910128099356Search in Google Scholar

24. Marko-Kucsera M, Vecsei L, Paulik E. Association of cardiovascular risk factors and Parkinson’s disease - case-control study in South East Hungary. Ideggyogy Sz. 2018 Jan;71(1–2):57–62.10.18071/isz.71.005729465901Search in Google Scholar

25. Lu L, Fu D-L, Li H-Q, Liu A-J, Li J-H, Zheng G-Q. Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PLoS One. 2014;9(1):e85781.10.1371/journal.pone.0085781389752024465703Search in Google Scholar

26. Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord. 2011 Feb;17(2):77–83.10.1016/j.parkreldis.2010.08.022302158720851033Search in Google Scholar

27. Mendoza-Velasquez JJ, Flores-Vazquez JF, Barron-Velazquez E, Sosa-Ortiz AL, Illigens B-MW, Siepmann T. Autonomic dysfunction in alpha-synucleinopathies. Front Neurol. 2019;10:363.10.3389/fneur.2019.00363647418131031694Search in Google Scholar

28. Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res. 2016 Apr;26(2):97–105.10.1007/s10286-015-0336-426801189Search in Google Scholar

29. Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res. 2016 Feb;26(1):15–21.10.1007/s10286-015-0324-826613721Search in Google Scholar

30. Qiu C, Hu G, Kivipelto M, Laatikainen T, Antikainen R, Fratiglioni L, et al. Association of blood pressure and hyper-tension with the risk of Parkinson disease: the National FINRISK Study. Hypertens (Dallas, Tex 1979). 2011 Jun;57(6):1094–100.10.1161/HYPERTENSIONAHA.111.17124921536985Search in Google Scholar

31. Jain S, Ton TG, Perera S, Zheng Y, Stein PK, Thacker E, et al. Cardiovascular physiology in premotor Parkinson’s disease: a neuroepidemiologic study. Mov Disord. 2012 Jul;27(8):988–95.10.1002/mds.24979365237722700356Search in Google Scholar

32. Li Q, Wang C, Tang H, Chen S, Ma J. Stroke and coronary artery disease are associated with Parkinson’s disease. Can J Neurol Sci. 2018 Sep;45(5):559–65.10.1017/cjn.2018.5630001757Search in Google Scholar

33. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007 Oct;69(17):1688–95.10.1212/01.wnl.0000271883.45010.8a239107717761552Search in Google Scholar

34. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci. 2010 Jun;293(1–2):82–6.10.1016/j.jns.2010.03.00220347450Search in Google Scholar

35. Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and parkinsonism. J Clin Neurosci Off J Neurosurg Soc Australas. 2018 Jul; 53:1–5.10.1016/j.jocn.2018.04.03129706419Search in Google Scholar

36. Ronkainen J, Agreus L. Epidemiology of reflux symptoms and GORD. Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):325–37.10.1016/j.bpg.2013.06.00823998972Search in Google Scholar

37. Aerts R, Penninckx F. The burden of gallstone disease in Europe. Aliment Pharmacol Ther. 2003 Nov;18 Suppl 3:49–53.10.1046/j.0953-0673.2003.01721.x14531741Search in Google Scholar

38. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord. 2008 Jun;23(8):1065–75.10.1002/mds.2205118442139Search in Google Scholar

39. Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson’s disease: a questionnaire-based study. Parkinsons Dis. 2013;2013:742128.10.1155/2013/742128358311823476890Search in Google Scholar

40. Makaroff L, Gunn A, Gervasoni C, Richy F. Gastrointestinal disorders in Parkinson’s disease: prevalence and health outcomes in a US claims database. J Parkinsons Dis. 2011;1(1):65–74.10.3233/JPD-2011-00123939257Search in Google Scholar

41. Modaine P, Levy S, Masmoudi K, Capron D, Votte A, Josse C, et al. Parkinson’s disease: a new risk factor for gallstone disease? Vol. 23, Journal of hepatology. Netherlands; 1995. p. 484.10.1016/0168-8278(95)80213-4Search in Google Scholar

42. Maki T, Sonoda Y, Sugita K. [Gallstone and Parkinson’s disease--ultrasound echography study]. Rinsho Shinkeigaku. 1990 Jul;30(7):728–30.Search in Google Scholar

43. Gerstenbrand F, Poewe W. Dopaminergic-peptidergic interactions in extrapyramidal disorders: a review of the clinical evidence. Adv Neurol. 1987;45:67–73.Search in Google Scholar